Comparison of St John's wort and imipramine for treating depression: randomised controlled trial
- 2 September 2000
- Vol. 321 (7260) , 536-539
- https://doi.org/10.1136/bmj.321.7260.536
Abstract
Objectives: To compare the efficacy and tolerability of Hypericum perforatum (St John's wort extract) with imipramine in patients with mild to moderate depression. Design: Randomised, multicentre, double blind, parallel group trial. Setting: 40 outpatient clinics in Germany. Participants: 324 outpatients with mild to moderate depression. Intervention: 75 mg imipramine twice daily or 250 mg hypericum extract ZE 117 twice daily for 6 weeks. Main outcome measures: Hamilton depression rating scale, clinical global impression scale, and patient's global impression scale. Results: Among the 157 participants taking hypericum mean scores on the Hamilton depression scale decreased from 22.4 at baseline to 12.00 at end point; among the 167 participants taking imipramine they fell from 22.1 to 12.75. Mean clinical global impression scores at end point were 2.22 out of 7 for the hypericum group and 2.42 for the imipramine group. On the 7 point self assessments of global improvement completed by participants (score of 1 indicating “very much improved” and 7 indicating “very much deteriorated”) mean scores were 2.44 in the hypericum group and 2.60 in the imipramine group. None of the differences between treatment groups were significant. However, the mean score on the anxiety-somatisation subscale of the Hamilton scale (3.79 in the hypericum group and 4.26 in the imipramine group) indicated a significant advantage for hypericum relative to imipramine. Mean scores on the 5 point scale used by participants to assess tolerability (score of 1 indicating excellent tolerability and 5 indicating very poor tolerability) were better for hypericum (1.67) than imipramine (2.35). Adverse events occurred in 62/157 (39%) participants taking hypericum and in 105/167 (63%) taking imipramine. 4 (3%) participants taking hypericum withdrew because of adverse events compared with 26 (16%) taking imipramine. Conclusions: This Hypericum perforatum extract is therapeutically equivalent to imipramine in treating mild to moderate depression, but patients tolerate hypericum better.Keywords
This publication has 18 references indexed in Scilit:
- Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks Commentary: Has hypericum found its place in antidepressant treatment?BMJ, 1999
- Efficacy and Tolerability of St. John's Wort Extract LI 160 Versus Imipramine in Patients with Severe Depressive Episodes According to ICD-10Pharmacopsychiatry, 1997
- LI 160, an Extract of St. John's Wort, Versus Amitriptyline in Mildly to Moderately Depressed Outpatients - A Controlled 6-Week Clinical TrialPharmacopsychiatry, 1997
- St John's wort for depression--an overview and meta-analysis of randomised clinical trialsBMJ, 1996
- St John's wort as an antidepressantBMJ, 1996
- Trials to assess equivalence: the importance of rigorous methodsBMJ, 1996
- Comparative Study of Cerebral Ventricular Dilation and Cognitive Function in Patients with Alzheimer's Disease of Early versus Late OnsetJournal of Geriatric Psychiatry and Neurology, 1994
- A New Italian Pedigree with Early-Onset Alzheimer's DiseaseJournal of Geriatric Psychiatry and Neurology, 1994
- Reliability and Validity of the Short Portable Mental Status Questionnaire Administered by TelephoneJournal of Geriatric Psychiatry and Neurology, 1994
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960